Thoracic Cancer | |
Nimotuzumab combined with gemcitabine and cisplatin as second‐line chemotherapy for advanced non‐small‐cell lung cancer | |
Hua-qing Wang2  Yangang Ren1  Zheng-zi Qian2  Kai Fu3  Hui-lai Zhang3  Wei Li3  Yun Hou3  Shi-yong Zhou3  Xi-shan Hao3  | |
[1] Editorial Department of Chinese Journal of Practical Internal Medicine, China Medical University, ShenYang, China;Department of Radiation and Medical Oncology, Zhongnan Hospital, Hubei Cancer Clinical Study Center, Wuhan University, Wuhan, China;Department of Medical Oncology, Tianjin Medical University Cancer Hospital and Institute, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China | |
关键词: Advanced non‐small‐cell lung cancer; combined therapy; nimotuzumab; second‐line chemotherapy; | |
DOI : 10.1111/j.1759-7714.2011.00083.x | |
来源: Wiley | |
【 摘 要 】
Objective: To evaluate the efficacy and safety of nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) and to investigate the association of the status of KRAS gene mutation and epidermal growth factor receptor (EGFR) genotype with clinical outcome. Methods: Twenty-eight patients with advanced NSCLC were enrolled in this single center, uncontrolled pilot clinical study. All the patients developed drug resistance or disease progression after first-line chemotherapy of either a docetaxel + cisplatin regimen or a vinorelbine + cisplatin regimen and then received nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy. Eight cases were stage IIIB and 20 were stage IV. An i.v. dosage regimen of 200 mg of nimotuzumab was given as a single dose, injected into the patient at days 1, 8 and 15; i.v. gemcitabine was injected at a dose of 1000 mg/m2 at days 1 and 8 and cisplatin (25 mg/m2 i.v.) at days 1, 2 and 3. Each patient received four or more therapeutic cycles. The efficacy and toxic reactions were evaluated, as well as time to progression and overall survival. Results: In total, 28 patients with advanced NSCLC received 101 therapeutic cycles. The mean cycle number was 3.6. Median time to progression was 4.9 (2.5–6.5) months; median overall survival and 1-year survival rate were 9.8 months and 48.5%, respectively. There was one case of complete response, six cases of partial response, 11 cases of stable disease and 10 cases of progressive disease. Response rate was 25%, and clinical benefit rate was 64.3%. Major toxic reactions were bone marrow suppression and gastrointestinal reaction. Only one patient developed grade I acneiform eruption. Conclusion: Nimotuzumab combined with gemcitabine and cisplatin as second-line chemotherapy for advanced NSCLC was active and well-tolerated in this setting. Patients with EGFR amplification and KRAS gene wild type had a better prognosis. Prospective, randomized, controlled, large-scale clinical studies are needed to confirm the results.Abstract
【 授权许可】
Unknown
© 2011 Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202107150006479ZK.pdf | 149KB | download |